Our Target - Cell Death
Cell death is a devastating component of a spectrum of diseases and results in severe morbidity. FasT Biopharma’s candidate therapeutics block a major pathway involved in the unwanted death of cells, providing potential breakthrough therapies.
By targeting Fas ligand (FasL) we can prevent apoptotic cell death, which can otherwise lead to blindness, cancer immune failure, diabetes, viral pathology (including effects of Covid-19), liver degeneration and lung fibrosis. Thus the potential of therapies blocking FasL is vast.